Brief: Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation By FDA
07/05/2020 12:56
May 7 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA'S CORE DRUG CANDIDATE HQP1351 GRANTED
FAST
TRACK DESIGNATION BY THE US FDA, MARKING ANOTHER MILESTONE IN
ITS DEVELOPMENT
Source text for Eikon: ID:nPnLh5sFa
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up